Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is a heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, clinical biochemistry, rheumatology, advanced therapies or transfusional medicine. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

268

total

1598

impact factor

5.96

average impact factor

Group Leader: Antònia Agustí Escasany

team

zoom

download

The group is a Special Group of Research recognized by AGAUR GenCat, and is a partner of the European Consortium “EU PE&PV Network” (European Pharmacoepidemiology and Pharmacovigilance Network”. Within this consortium a new study started “COVID-19 infection and medicines in pregnancy: a multinational registry based study (CONSIGN)”. Another new project started during the year was a “Multicenter national study on late sided effects in patients with a non-Hodgkin’s lymphoma of diffuse large B-cell treated with CAR-T cell therapy (not financed)”. Regarding to COVID-19, the group has participated in a UHVH patient registry and has performed the study “Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial”. The group is also taking part in the VHIR Task Forte COVID-19. Finally, our group has continued the international training activities through its participation in the European master of pharmacoepidemiology (Eu2P) and hosting fellow researchers.

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Group Leader: Antònia Agustí Escasany

Research Areas